Literature DB >> 29113028

Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis.

Teresa García-Lezana1, Imma Raurell1,2, Miren Bravo1,2, Manuel Torres-Arauz1, María Teresa Salcedo3, Alba Santiago4, Andreu Schoenenberger4, Chaysavanh Manichanh2,4, Joan Genescà1,2, María Martell1,2, Salvador Augustin1,2.   

Abstract

Portal hypertension (PH) drives most of the clinical complications in chronic liver diseases. However, its progression in nonalcoholic steatohepatitis (NASH) and its association with the intestinal microbiota (IM) have been scarcely studied. Our aim was to investigate the role of the IM in the mechanisms leading to PH in early NASH. The experimental design was divided in two stages. In stage 1, Sprague-Dawley rats were fed for 8 weeks a high-fat, high-glucose/fructose diet (HFGFD) or a control diet/water (CD). Representative rats were selected as IM donors for stage 2. In stage 2, additional HFGFD and CD rats underwent intestinal decontamination, followed by IM transplantation with feces from opposite-diet donors (heterologous transplant) or autologous fecal transplant (as controls), generating four groups: CD-autotransplanted, CD-transplanted, HFGFD-autotransplanted, HFGFD-transplanted. After IM transplantation, the original diet was maintained for 12-14 days until death. HFGFD rats developed obesity, insulin resistance, NASH without fibrosis but with PH, intrahepatic endothelial dysfunction, and IM dysbiosis. In HFGFD rats, transplantation with feces from CD donors caused a significant reduction of PH to levels comparable to CD without significant changes in NASH histology. The reduction in PH was due to a 31% decrease of intrahepatic vascular resistance compared to the HFGFD-autotransplanted group (P < 0.05). This effect occurs through restoration of the sensitivity to insulin of the hepatic protein kinase B-dependent endothelial nitric oxide synthase signaling pathway.
CONCLUSION: The IM exerts a direct influence in the development of PH in rats with diet-induced NASH and dysbiosis; PH, insulin resistance, and endothelial dysfunction revert when a healthy IM is restored. (Hepatology 2018;67:1485-1498).
© 2017 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2018        PMID: 29113028     DOI: 10.1002/hep.29646

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  29 in total

Review 1.  Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function.

Authors:  Suzanne R Sharpton; Veeral Ajmera; Rohit Loomba
Journal:  Clin Gastroenterol Hepatol       Date:  2018-09-07       Impact factor: 11.382

2.  An update on the role of the microbiome in non-alcoholic fatty liver disease pathogenesis, diagnosis, and treatment.

Authors:  Marialena Mouzaki; Rohit Loomba
Journal:  Curr Treat Options Gastroenterol       Date:  2020-05-02

3.  The concomitant loss of APC and HNF4α in adult hepatocytes does not contribute to hepatocarcinogenesis driven by β-catenin activation.

Authors:  Chiara Sartor; Laura Bachelot; Cécile Godard; Franck Lager; Gilles Renault; Frank J Gonzalez; Christine Perret; Angélique Gougelet; Sabine Colnot
Journal:  Liver Int       Date:  2019-02-24       Impact factor: 5.828

Review 4.  The promise of the gut microbiome as part of individualized treatment strategies.

Authors:  Daniel A Schupack; Ruben A T Mars; Dayne H Voelker; Jithma P Abeykoon; Purna C Kashyap
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-08-27       Impact factor: 46.802

Review 5.  Understanding the cellular interactome of non-alcoholic fatty liver disease.

Authors:  Sebastian J Wallace; Frank Tacke; Robert F Schwabe; Neil C Henderson
Journal:  JHEP Rep       Date:  2022-06-15

Review 6.  The Crosstalk Between Liver Sinusoidal Endothelial Cells and Hepatic Microenvironment in NASH Related Liver Fibrosis.

Authors:  Wei Du; Lin Wang
Journal:  Front Immunol       Date:  2022-06-28       Impact factor: 8.786

7.  Synergic effect of atorvastatin and ambrisentan on sinusoidal and hemodynamic alterations in a rat model of NASH.

Authors:  Miren Bravo; Imma Raurell; Aurora Barberá; Diana Hide; Mar Gil; Federico Estrella; María Teresa Salcedo; Salvador Augustin; Joan Genescà; María Martell
Journal:  Dis Model Mech       Date:  2021-05-20       Impact factor: 5.758

Review 8.  Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect.

Authors:  Rajiv Heda; Masahiko Yazawa; Michelle Shi; Madhu Bhaskaran; Fuad Zain Aloor; Paul J Thuluvath; Sanjaya K Satapathy
Journal:  World J Gastroenterol       Date:  2021-05-07       Impact factor: 5.742

Review 9.  Intestinal Barrier and Permeability in Health, Obesity and NAFLD.

Authors:  Piero Portincasa; Leonilde Bonfrate; Mohamad Khalil; Maria De Angelis; Francesco Maria Calabrese; Mauro D'Amato; David Q-H Wang; Agostino Di Ciaula
Journal:  Biomedicines       Date:  2021-12-31

Review 10.  Microbiota reprogramming for treatment of alcohol-related liver disease.

Authors:  Mohamed Tausif Siddiqui; Gail A M Cresci
Journal:  Transl Res       Date:  2020-07-17       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.